Salute e Benessere
Osteoporosis Market Set to Expand Significantly During the Forecast Period (2025-2034) Due to Rising Aging Population and Novel Therapeutics | DelveInsight
Discover the osteoporosis new treatment @
The global burden of osteoporosis is increasing rapidly due to the growing elderly population, especially among postmenopausal women. As life expectancy rises, the prevalence of age-related bone loss and fragility fractures continues to drive the demand for osteoporosis diagnosis and treatment.
Public health initiatives and awareness campaigns emphasizing bone health, fracture prevention, and early diagnosis are increasing treatment rates. Healthcare organizations and patient advocacy groups are actively promoting screening for postmenopausal and elderly populations.
A robust range of treatments, including , provides personalized approaches.
The expected launch of emerging therapies such as (EnteraBio), (Angitia Biopharmaceuticals), (Rani Therapeutics), and others will change the dynamics of the osteoporosis market in the coming years.
The emergence of oral anabolic therapies, such as , addresses the accessibility and compliance limitations of subcutaneous injectables, offering improved adherence, convenience, and clinical adoption in osteoporosis management.
Agents like , which have both anabolic and antiresorptive effects, open new avenues for faster and more robust improvements in bone density, especially in patients at high risk of fractures.
The osteoporosis treatment landscape is primarily dominated by pharmacological interventions, broadly categorized into (such as bisphosphonates, estrogen agonists/antagonists, estrogens, calcitonin, and denosumab), (including teriparatide and abaloparatide), and like romosozumab. Beyond these established therapies, additional anti-resorptive options include and , notably raloxifene, lasofoxifene, and bazedoxifene. , such as calcium and vitamin D, also contribute to supportive benefits for patients with osteoporosis.
In , the approved , a biosimilar of FORTEO, for the treatment of osteoporosis in patients at high risk of fractures. When conservative approaches, such as medication, exercise, and diet, fail to produce results within three months, become necessary. Two minimally invasive options for spinal osteoporotic fractures include and .
Currently, the osteoporosis market is largely driven by biosimilars and generics, which continue to show strong therapeutic promise. The pipeline, however, remains relatively limited, with only a few investigational products under development by companies such as . is actively seeking collaborative partnerships with organizations aligned with its mission to address disorders linked to the sclerostin pathway, including osteoporosis. Notably, represents a novel approach in this space, as the first oral, osteoanabolic (bone-building) tablet designed for once-daily use, offering a potential dual mechanism of action to bridge current treatment gaps.
To know more about osteoporosis treatment options, visit @
The potential osteoporosis drugs in clinical trials include (EnteraBio), (Angitia Biopharmaceuticals), (Rani Therapeutics), and others.
is being developed as the first oral, once-daily osteoanabolic tablet aimed at postmenopausal women with low bone mineral density (BMD) and high-risk osteoporosis who have not experienced prior fractures. In a placebo-controlled, dose-ranging Phase II trial, EB613 achieved both its primary and secondary endpoints. The planned Phase III registrational trial for EB613 is structured to meet the quantitative BMD benchmarks proposed by SABRE and is expected to commence in the second half of 2025. Following FDA Type C and D meetings, the company received alignment on the use of a placebo, the defined patient population, and BMD as a key endpoint. A BMD Endpoint Qualification Ruling and a SABRE update are anticipated in 2025.
represents the original RaniPill capsule formulation containing the parathyroid hormone analog PTH(1-34), designed to treat osteoporosis. Rani Therapeutics has completed a pre-Investigational New Drug (IND) meeting with the FDA for RT-102, which utilizes the RaniPill GO platform and a proprietary human PTH(1-34) analog formulation. The company anticipates initiating a Phase II clinical trial for RT-102.
is a bispecific antibody under development for osteoporosis that simultaneously targets sclerostin and
DKK1 , two key inhibitors of WNT signaling in osteoblasts and bone metabolism. By neutralizing both molecules, AGA2118 is intended to prevent compensatory upregulation of either target, thereby enhancing BMD improvements in osteoporotic patients. Angitia, which fully owns the bispecific antibody, announced in
November 2024 the first patient dosing in ARTEMIS, its Phase II clinical study evaluating AGA2118 for osteoporosis.
The anticipated launch of these emerging therapies are poised to transform the osteoporosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the osteoporosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about therapy for osteoporosis @
Osteoporosis is a chronic bone disease characterized by a decrease in bone mass and deterioration of bone tissue, leading to increased fragility and a higher risk of fractures. It occurs when the balance between bone formation and bone resorption is disrupted; bones lose minerals such as calcium faster than they are replaced, making them weak and porous. Often referred to as the "silent disease," osteoporosis typically progresses without noticeable symptoms until a fracture occurs, most commonly in the hip, spine, or wrist. It primarily affects postmenopausal women due to hormonal changes, but can also impact men and individuals with certain medical conditions or lifestyle factors. Early diagnosis and preventive measures, including adequate calcium and vitamin D intake, regular exercise, and medication when necessary, are crucial for maintaining bone health and reducing fracture risk.
The osteoporosis epidemiology section provides insights into the historical and current osteoporosis patient pool and forecasted trends for the leading markets. Osteoporosis affects over people in the UK, with more than people receiving hospital treatment for fragility fractures every year as a result of osteoporosis.
The osteoporosis market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Download the report to understand which factors are driving osteoporosis therapeutics market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteoporosis companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-menopausal osteoporosis companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key post-menopausal osteoporosis companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteoarthritis companies including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/osteoporosis-market-set-to-expand-significantly-during-the-forecast-period-20252034-due-to-rising-aging-population-and-novel-therapeutics--delveinsight-302616599.html